InflammationTCRNCT06122038
Impact of Powdered Tart Cherries on Recovery From Repeated Sprints
A study testing Tart Cherry Extract Powder in people with Inflammation and Oxidative Stress, run by Lindenwood University at 1 site in United States.
Trial summary
The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females. Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Inflammation, Oxidative Stress, Soreness, Muscle
- What is being tested?
- Tart Cherry Extract Powder
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 25 Apr 2023to 20 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male and female (n=40) participants between the ages of 18 - 35 years of age will finish the study protocol. An even distribution of males (n=20) and females (n=20) is planned.
- Participating in some form of exercise at least four days per week with at least two days consisting of some form of high-intensity exercise for the past six months.
- Examples include regular gym attendance to complete resistance training, interval exercise, or participation in some form of organized physical activity involving high-speed running or other forms of high-intensity exercise.
- Have a body mass index (BMI) range of 18.0 - 30.0 kg/m2. Males with a body mass index greater than 30.0 kg/m2, but a body fat percentage less than 27.5% fat will be accepted into the study. Females with a body mass index greater than 30.0 kg/m2, but a body fat percentage less than 32.5% fat will be accepted into the study.
Who cannot join
- Participant has a positive medical history of heart disease/cardiovascular disease, uncontrolled hypertension (140/90 or greater mmHg), kidney disease (dialysis or renal failure), hepatic impairment or disease, or Type I or Type II diabetes.
- Participant has a positive medical history of unstable thyroid disease, previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorder (i.e., HIV/AIDS), a history of cancer (except localized skin cancer without metastases or in situ cervical cancer within five years prior to screening visit.
- Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g. dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)
- Positive medical history for any neurological condition or neurological disease
- Currently smoke or have quit within the past six months
- Current daily use of aspirin, NSAIDS, naproxen sodium, COX-2 inhibitors, or any other over-the-counter or prescribed medication indicated for pain relief.
Show all 13Show fewer
- Intake of any dietary supplement known or purported to impact muscle repair and recovery such as antioxidants, curcumin, turmeric, branched-chain amino acids, vitamin D, tart cherry, pomegranate, fish oils, or creatine monohydrate.
- Individuals who indicate they are actively involved in any form of a dietary program in the past 30 days to lose weight
- Participants who are lactating, pregnant or planning to become pregnant
- Have a known sensitivity or allergy to any of the study products
- Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data
- History of alcohol or substance abuse in the 12 months prior to screening
- Receipt or use of an investigational product in another research study within 28 days prior to baseline testing
Trial locations and contacts
1 site in 1 country.
United States1 site
Exercise and Performance Nutrition Laboratory
Saint Charles, Missouri, 63301
About this study
Official title: Impact of Powdered Tart Cherries on Recovery From Repeated Sprints in Trained Males and Females
The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females.
Read the detailed description
The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females. This study will utilize a randomized, double-blind, placebo group study design. Prior to any data collection, potential participants will be explained the protocol and then review and sign an IRB-approved consent form. Healthy male and female (n=40) participants who report regularly practicing or competing in high-intensity multi-modal resistance based exercise will complete the study protocol.
- Conditions
- Inflammation, Oxidative Stress, Soreness, Muscle, Muscle Damage
- Being tested
- Tart Cherry Extract Powder, Placebo
- Keywords
- Tart Cherry, Inflammation, Muscle Soreness, Muscle Damage
- Medical subject headings
- Inflammation, Myalgia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tart Cherry Extract PowderDietary supplement
Tart Cherry Extract Powder (ADSO Naturals). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
PlaceboDietary supplement
Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Rice Flour. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days. Receives: Dietary Supplement: Placebo |
| Tart Cherry Extract Powder | Experimental | Tart Cherry Extract Powder (ADSO Naturals). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days. Receives: Dietary Supplement: Tart Cherry Extract Powder |
What is being measured
The primary outcome is the main question the study is designed to answer.
Counter movement Jump Height
Jump height from counter movement jump
Measured: 10 days
Counter movement jump peak propulsive force (N)
Peak propulsive force (N) from counter movement jump
Measured: 10 days
Counter movement jump relative breaking force (N)
relative breaking force (N/kg) from counter movement jump
Measured: 10 days
Isokinetic knee extension maximal voluntary contraction.
Peak isokinetic knee extension force (N) from a isokinetic knee extension exercise using a Biodex System 3
Measured: 10 days
Isometric mid-thigh pull maximal voluntary contraction
Isometric maximal voluntary contraction peak force will be measured using an isometric mid-thigh pull assessment. Peak force production will be measured in Newtons.
Measured: 10 days
Perceived recovery Visual Analog Scale
Perceived recovery Visual Analog Scale ranging from 0 (worst) to 100 (best)
Measured: 10 days
Perceived soreness Visual Analog Scale
Perceived soreness Visual Analog Scale ranging from 0 (worst) to 100 (best)
Measured: 10 days
Pain to Pressure threshold
Pain to Pressure threshold from algometry (higher = less sore). Minimum values are 0 N, maximum values are 110 N
Measured: 10 days
Changes in Creatine Kinase concentrations
Changes in Creatine kinase concentrations following damaging exercise
Measured: 10 days
Changes in Creatine Kinase-myocardial band concentrations
Changes in Creatine kinase-myocardial band concentrations following damaging exercise
Measured: 10 days
Sprint time
Fastest and average sprint time during 15 30-meter sprint recorded using digitally timed timing gates
Measured: Baseline
Secondary outcomes (10)
Peak power
Peak power during a wingate anaerobic test
Measured: 10 days
Changes in Protein carbonyls concentration
Protein carbonyls concentration changes
Measured: 10 days
Changes in 8-isoprostane concentration
8-isoprostane concentration changes
Measured: 10 days
Changes in testosterone-cortisol ratio
Testosterone-cortisol ratio changes
Measured: 10 days
Changes in TNF-alpha concentration
Changes in TNF-alpha concentration
Measured: 10 days
Changes in IL-6 concentration
Changes in IL-6 concentration
Measured: 10 days
Changes in IL-10 concentration
Changes in IL-10 concentration
Measured: 10 days
Desire to exercise visual analog scale
Desire to exercise visual analog scale (0 = not ready to train, 100 = very ready to train)
Measured: 10 days
Pittsburgh sleepiness Scale Score
Pittsburgh sleepiness Scale Score (lower scores indicate higher level of sleepiness)
Measured: 10 days
Changes in Uric Acid Concentrations
Changes in Uric Acid concentrations
Measured: 10 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2023
- Study start25 Apr 2023
- Primary completion20 Dec 2023
- Study completion20 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InflammationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study will utilize a randomized, double-blind, placebo group study design
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lindenwood University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Chad M Kerksick, PhD, Principal investigator, Lindenwood University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06122038
- Sponsor's protocol ID
- IRB-23-11
- Acronym
- TCR
- Status last verified
- Apr 2024
- First submitted
- 15 May 2023
- Last updated
- 13 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Powdered Tart Cherries on Recovery From Repeated Sprints in Trained Males and Females
- ClinicalTrials.gov ID
- NCT06122038
- Acronym / sponsor ID
- TCR / IRB-23-11
- Conditions
- Inflammation, Oxidative Stress, Soreness, Muscle, Muscle Damage
- Keywords
- Tart Cherry, Inflammation, Muscle Soreness, Muscle Damage
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Lindenwood UniversityUniversity, hospital or other
- Study start
- 25 Apr 2023 (actual)
- Primary completion
- 20 Dec 2023 (actual)
- Study completion
- 20 Dec 2023 (actual)
- First posted
- 8 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females.
Detailed description
The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females. This study will utilize a randomized, double-blind, placebo group study design. Prior to any data collection, potential participants will be explained the protocol and then review and sign an IRB-approved consent form. Healthy male and female (n=40) participants who report regularly practicing or competing in high-intensity multi-modal resistance based exercise will complete the study protocol.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- This study will utilize a randomized, double-blind, placebo group study design
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Dietary Supplement: PlaceboRice Flour. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days. |
| Tart Cherry Extract Powder | Experimental | Dietary Supplement: Tart Cherry Extract PowderTart Cherry Extract Powder (ADSO Naturals). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy male and female (n=40) participants between the ages of 18 - 35 years of age will finish the study protocol. An even distribution of males (n=20) and females (n=20) is planned.
- Participating in some form of exercise at least four days per week with at least two days consisting of some form of high-intensity exercise for the past six months.
- Examples include regular gym attendance to complete resistance training, interval exercise, or participation in some form of organized physical activity involving high-speed running or other forms of high-intensity exercise.
- Have a body mass index (BMI) range of 18.0 - 30.0 kg/m2. Males with a body mass index greater than 30.0 kg/m2, but a body fat percentage less than 27.5% fat will be accepted into the study. Females with a body mass index greater than 30.0 kg/m2, but a body fat percentage less than 32.5% fat will be accepted into the study.
Key exclusion criteria (13 listed)
- Participant has a positive medical history of heart disease/cardiovascular disease, uncontrolled hypertension (140/90 or greater mmHg), kidney disease (dialysis or renal failure), hepatic impairment or disease, or Type I or Type II diabetes.
- Participant has a positive medical history of unstable thyroid disease, previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorder (i.e., HIV/AIDS), a history of cancer (except localized skin cancer without metastases or in situ cervical cancer within five years prior to screening visit.
- Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g. dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)
- Positive medical history for any neurological condition or neurological disease
- Currently smoke or have quit within the past six months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tart Cherry Extract PowderTart Cherry Extract Powder (ADSO Naturals). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days. | Dietary supplement | Tart Cherry Extract Powder |
| PlaceboRice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days. | Dietary supplement | Placebo |
Primary outcome
Counter movement Jump Height
Time frame: 10 days
Jump height from counter movement jump
Counter movement jump peak propulsive force (N)
Time frame: 10 days
Peak propulsive force (N) from counter movement jump
Counter movement jump relative breaking force (N)
Time frame: 10 days
relative breaking force (N/kg) from counter movement jump
Isokinetic knee extension maximal voluntary contraction.
Time frame: 10 days
Peak isokinetic knee extension force (N) from a isokinetic knee extension exercise using a Biodex System 3
Isometric mid-thigh pull maximal voluntary contraction
Time frame: 10 days
Isometric maximal voluntary contraction peak force will be measured using an isometric mid-thigh pull assessment. Peak force production will be measured in Newtons.
Perceived recovery Visual Analog Scale
Time frame: 10 days
Perceived recovery Visual Analog Scale ranging from 0 (worst) to 100 (best)
Perceived soreness Visual Analog Scale
Time frame: 10 days
Perceived soreness Visual Analog Scale ranging from 0 (worst) to 100 (best)
Pain to Pressure threshold
Time frame: 10 days
Pain to Pressure threshold from algometry (higher = less sore). Minimum values are 0 N, maximum values are 110 N
Changes in Creatine Kinase concentrations
Time frame: 10 days
Changes in Creatine kinase concentrations following damaging exercise
Changes in Creatine Kinase-myocardial band concentrations
Time frame: 10 days
Changes in Creatine kinase-myocardial band concentrations following damaging exercise
Sprint time
Time frame: Baseline
Fastest and average sprint time during 15 30-meter sprint recorded using digitally timed timing gates
10 secondary outcomes
Peak power
Time frame: 10 days
Changes in Protein carbonyls concentration
Time frame: 10 days
Changes in 8-isoprostane concentration
Time frame: 10 days
Changes in testosterone-cortisol ratio
Time frame: 10 days
Changes in TNF-alpha concentration
Time frame: 10 days
Changes in IL-6 concentration
Time frame: 10 days
Changes in IL-10 concentration
Time frame: 10 days
Desire to exercise visual analog scale
Time frame: 10 days
Pittsburgh sleepiness Scale Score
Time frame: 10 days
Changes in Uric Acid Concentrations
Time frame: 10 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Inflammation
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chad M Kerksick, PhD principal investigator
Lindenwood University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tart Cherry Extract Powder in people with Inflammation and Oxidative Stress, run by Lindenwood University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Counter movement Jump Height (time frame: 10 days). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.